For research use only. Not for therapeutic Use.
(9R,12aR)-AZD4747 (Cat No.: I040107) is a selective small-molecule inhibitor targeting the TANK-binding kinase 1 (TBK1), an enzyme involved in the innate immune response, inflammation, and cancer progression. By inhibiting TBK1, (9R,12aR)-AZD4747 has potential therapeutic applications in diseases where aberrant TBK1 activation plays a role, such as neuroinflammatory conditions, autoimmune disorders, and cancers. Preclinical studies suggest it could help modulate immune responses, reduce inflammation, and slow tumor growth, offering a promising strategy for precision medicine in treating these diseases.
| Synonyms | 1-[(4aR)-8-(2-chloro-6-hydroxyphenyl)-7-fluoro-9-prop-1-ynyl-1,2,4,4a,5,11-hexahydropyrazino[2,1-c][1,4]benzoxazepin-3-yl]prop-2-en-1-one |
| Molecular Formula | C24H22ClFN2O3 |
| Purity | ≥95% |
| InChI | InChI=1S/C24H22ClFN2O3/c1-3-6-15-11-16-12-27-9-10-28(20(30)4-2)13-17(27)14-31-24(16)23(26)21(15)22-18(25)7-5-8-19(22)29/h4-5,7-8,11,17,29H,2,9-10,12-14H2,1H3/t17-/m1/s1 |
| InChIKey | CNQOLVBNICGIJB-QGZVFWFLSA-N |
| SMILES | CC#CC1=C(C(=C2C(=C1)CN3CCN(CC3CO2)C(=O)C=C)F)C4=C(C=CC=C4Cl)O |
| Reference | [1]. Kettle JG, et al. Discovery of AZD4747, a Potent and Selective Inhibitor of Mutant GTPase KRASG12C with Demonstrable CNS Penetration. J Med Chem. 2023 Jul 13;66(13):9147-9160. |
-AZD4747.gif)